Answers are grounded in this paper and cite their sources.
Meibomian gland dysfunction (MGD) is a major cause of evaporative dry eye disease. Current treatments mainly focus on either relieving meibomian gland obstruction or controlling inflammation, but therapeutic outcomes in moderate-to-severe MGD remain limited. This study evaluates a novel combination therapy integrating meibomian gland probing (MGP) with autologous platelet-rich plasma (PRP) mesotherapy to simultaneously target ductal obstruction and inflammatory dysfunction. This study included 30 patients (60 eyes) with bilateral moderate-to-severe MGD who were randomly allocated to the treatment or control group. Both eyes received the intervention assigned at the participant level. The treatment group received MGP combined with PRP mesotherapy, whereas the control group received conventional medical therapy. The participant was the unit of analysis, and bilateral ocular measurements were averaged at each time point. The prospectively specified primary outcome was the change in OSDI score from baseline to week 4. Secondary outcomes included changes in LLT, NIBUT, TMH, meibum quality, ocular redness, and MGL. Within-group changes and between-group differences in changes from baseline were analyzed using parametric or nonparametric tests, as appropriate. The Holm method was applied to adjust for multiple comparisons among the secondary outcomes. Compared with baseline, patients in the treatment group showed significant improvements in OSDI score, lipid layer thickness (LLT), tear meniscus height (TMH), meibum quality score, and Noninvasive tear breakup time (NIBUT) (all P < 0.05). Compared with the control group, the treatment group achieved significantly greater improvements in OSDI, LLT, and meibum quality score at 4 weeks post-treatment (all P < 0.05). MGP combined with PRP mesotherapy demonstrated favorable short-term efficacy and safety in patients with moderate-to-severe MGD. By improving both subjective symptoms and objective clinical outcomes, this combined treatment may offer a promising alternative for patients with MGD. http://clinicaltrials.gov , ChiCTR2600128838 (retrospectively registered July 27, 2026).
No takes yet. Share an insight, caveat, or question.
Qiu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: